CCM
UTHR icon

Catapult Capital Management’s United Therapeutics UTHR Stock Holding History

Catapult Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-22,500
Closed -$3.88M – 284
2015
Q1 		$3.88M Buy
22,500
+7,500
+50% +$1.14M 0.47% 69
2014
Q4 		$1.94M Buy
+15,000
New +$1.93M 0.49% 63

Other funds holding UTHR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Catapult Capital Management's UTHR Position: Q2 2015 in Review

Catapult Capital Management sold out of United Therapeutics (UTHR) in Q2 2015, closing a stake of 22,500 shares — an estimated $3.88M sold.

Catapult Capital Management first reported a position in UTHR in Q4 2014 and held it in 2 quarters. The position peaked at $3.88M in Q1 2015. 384 funds tracked by Wall St. Rank hold UTHR as of Q2 2015.

  • Catapult Capital Management reported no remaining United Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Catapult Capital Management sold 22,500 United Therapeutics shares in Q2 2015, an estimated $3.88M.
  • Catapult Capital Management first reported a position in United Therapeutics in Q4 2014 and held it in 2 quarters.
  • Catapult Capital Management's United Therapeutics position peaked at $3.88M in Q1 2015.
  • 384 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2015.

Based on Catapult Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.